Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam
Author of the article:
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
ROCKVILLE, Md. — Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers, today announced that Chief Executive Officer Dr. Gregory Glenn will take part in two sessions at the 27th World Vaccine Congress Europe, held October 19 to 21 at the RAI Convention Centre in Amsterdam.
Get the latest headlines, breaking news and columns.
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
A welcome email is on its way. If you don't see it, please check your junk folder.
The next issue of Top Stories will soon be in your inbox.
We encountered an issue signing you up. Please try again
Cancer & Therapeutic Vaccines Workshop panel, “Chronic Conditions and Off-Target Effects of Vaccines”
Monday, October 19, 2026, 12:15 to 13:00 CEST (6:15 to 7:00 am ET)
Atrium 2, RAI Convention Centre, Europaplein 24, Amsterdam
- Moderator: Robbert van der Most, Chief Executive Officer, Vaxxcellence
- Asimenia Angelidou, Assistant Professor of Paediatrics, Harvard Medical School
- Nicholas Perombelon, Head of Vaccines and Therapies for Infectious Diseases Office, European Medicines Agency
- Gregory Glenn, Chief Executive Officer, Pinion Immunotherapeutics
- Katharina Mühlhoff, Assistant Professor of Medicine, Heidelberg Institute of Global Health
Presentation, “Pinion’s AI-Designed mRNA Platform for Establishing Immune Control of EBV, from Mono to MS to Malignancy”
Wednesday, October 21, 2026, 14:15 to 14:30 CEST (8:15 to 8:30 am ET)
Track 1 (Infectious Diseases), RAI Convention Centre, Amsterdam
Gregory Glenn, Chief Executive Officer, Pinion Immunotherapeutics
Epstein Barr virus was the first virus shown to cause human cancer, and it infects most adults worldwide for life. There are no FDA approved EBV vaccines or treatments after 60 years of research. The connection between latent viral infection and chronic disease is a hot area of biology, and it is drawing growing attention from researchers, regulators and industry. Dr. Glenn will discuss how Pinion is designing mRNA immunotherapeutics intended to help adults restore immune control to prevent and cure disease stemming from EBV infections, building on the company’s HPV program, ARV-2001, which has an FDA cleared IND.
Dr. Glenn previously served as President of Research and Development at Novavax, where he led development of the Nuvaxovid COVID-19 vaccine.
Pinion Immunotherapeutics (ARV Technologies, Inc.) is a clinical-stage biotechnology company based in Maryland developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers. Its lead program, ARV-2001, targets HPV-16 cervical precancer as a potential non-surgical alternative to LEEP. The pipeline also includes programs in EBV, HSV, AML and KRAS-driven solid tumors, and a partnered HBV program. Learn more at pinionimt.com.
Contacts
| +1 717 327 1822
Dr. Glenn is available for interviews in Amsterdam October 19 to 21.
Join the Conversation
This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.